Journal of Medicinal Chemistry · 2014 · 118 citations · 36 references
MedicineOncologyPharmacologyCancer PharmacologyDrug DesignDrug DiscoveryTargeted Cancer TherapyTargeted Therapy PharmacokineticsTyrosine Kinase InhibitorsAlk Point MutationsAnaplastic Lymphoma Kinase InhibitionAnaplastic Lymphoma Kinase InhibitorsKinase Domain MutationsPoint MutationsResistance To Tyrosine Kinase InhibitorsSelective Tyrosine Kinase InhibitorsTyrosine Kinase Inhibitor Pharmacokinetics
Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is efficacious in ALK and ROS positive patients. Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease. The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine 8e, which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclinical pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).
36
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations
CH/? hydrogen bonds in crystals
Motohiro Nishio · CrystEngComm · 2004 · 1.4K citations
Identification of ALK as a major familial neuroblastoma predisposition gene
Yaël P. Mossé, Marci Laudenslager, Luca Longo et al. · Nature · 2008 · 1.4K citations
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama, Alice T. Shaw, Tahsin Khan et al. · Science Translational Medicine · 2012 · 1.3K citations
Medicine, Oncology, Pharmacology +17